Mustang Bio Announces Pricing of $4 Million Public Offering WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purchase up to 16,877,638 shares of commo...
Our trip to South Korea and China revealed Chinese shipbuilders are seeking growth to take on Korea’s established yards who are facing constraints. An eagerness to add capacity is one of our takeaways, as well as a gloomy outlook for Chinese real estate, which in our view should inevitably weigh on dry bulk demand.
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th anniversary with the company. The board of directors has initiated a search for a new chief executive officer which will consider both internal and external candidates. “During Mr. Coats’ tenure, Lexicon advanced two compounds through clin...
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024 THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in InformationU.S. Dial-in Number: (888) 317-6003International Dial-in Number: (412) 317-6061Conference ID: 5993982 Replay Informatio...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Crown Castle Highlights Actions its Board Has Implemented to Successfully Strengthen Foundation and Position Company for Long-Term Value Creation Urges Shareholders to Vote “FOR” ONLY Crown Castle’s 12 Qualified and Experienced Director Nominees on the WHITE Proxy Card Ted Miller’s Self-Serving Campaign Risks Derailing Important Work Underway and Is Not Aligned with Interests of Shareholders HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today sent a letter to shareholders in connection with its upcoming 2024 Annual Meeting of...
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that the Company will release its first quarter 2024 financial results after the market close on Thursday, May 9, 2024. The Company will also hold a conference call to discuss its financial results at 5:00 pm (Eastern Time) on the same day. The conference call can be accessed by dialing 1-844-826-3035 (domestic) or 1-412-317-5195 (international) and asking for the Cannae Holdings First Quarter 2024 Earnings Call. A telephonic replay will be available at the conclusion of the call and c...
Moody's Ratings (Moody's) has affirmed World Acceptance Corporation's (WRLD) B2 corporate family rating (CFR) and B3 senior unsecured rating. Moody's changed the company's outlook to stable from negative. RATINGS RATIONALE The change in outlook to stable reflects the company's improved asset qua...
Garrett Motion Reports First Quarter 2024 Financial Results First Quarter 2024 Highlights Net sales totaled $915 million, down 6% on a reported basis and 5% at constant currency*Net income totaled $66 million; Net income margin 7.2%Adjusted EBITDA* totaled $151 million; Adjusted EBITDA margin* of 16.5%Net cash provided by operating activities totaled $84 millionAdjusted free cash flow* totaled $68 millionRepurchased $109 million of Common Stock Reiterated Full Year 2024 Outlook Net sales of $3,870 million, flat on a reported and constant currency basis*Net income of $253 million; Net inc...
Ring Energy Announces Timing of First Quarter 2024 Earnings Release and Conference Call THE WOODLANDS, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced the timing of its first quarter 2024 earnings release and conference call. Ring plans to issue its first quarter 2024 earnings release after the close of trading on Monday, May 6, 2024. The Company has scheduled a conference call on Tuesday, May 7, 2024 at 11:00 a.m. ET to discuss its first quarter 2024 operational and financial results. To participate, interested p...
Merus gibt Annahme von Abstracts zur Präsentation auf der ASCO-Jahrestagung 2024 bekannt Petosemtamab in Kombination mit Pembrolizumab als 1L bei HNSCC – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt MCLA-145 als Monotherapie oder in Kombination mit Pembrolizumab bei soliden Tumoren – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt MCLA-129 bei NSCLC mit c-MET-Exon-14-Skipping-Mutationen – erste vorläufige klinische Daten für eine Posterpräsentation ausgewählt UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, April 25, 2...
Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO Pétosemtamab en association avec le pembrolizumab en traitement de première intention du carcinome épidermoïde de la tête et du cou : premières données cliniques provisoires sélectionnées pour une présentation orale rapide MCLA-145 en monothérapie ou en association avec le pembrolizumab dans les tumeurs solides : premières données cliniques provisoires sélectionnées pour une présentation orale rapide MCLA-129 dans le cancer bronchique non à petites cellules avec mutations conduisant à un saut de ...
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas’ interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston,...
Live Oak Bancshares, Inc. Reports First Quarter 2024 Results WILMINGTON, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (NYSE: LOB) (“Live Oak” or “the Company”) today reported first quarter of 2024 net income of $16.5 million, or $0.36 per diluted share. “The Live Oak model continued to prove its fortitude in the first quarter as our teams marched ahead to steadily grow both sides of the balance sheet and delivered exceptional service to our customers,” said Live Oak Chairman and CEO James S. (Chip) Mahan III. “In a challenging environment for our industry, I remain ...
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Me...
Crown Castle Issues Statement Regarding Ted Miller's Latest Attempt to Disrupt the Company's Momentum HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today issued the following statement: Consistent with the Boots Group’s approach throughout its campaign, Ted Miller has again pursued a litigation strategy that is attempting to interfere with Crown Castle’s critical strategic and operational initiatives. In his most recent motion, Ted Miller is seeking to prevent the Company from expanding the size of its Board, which the Board...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.